PCV84 Misdiagnosis and Mistreatment of ACE-Inhibitor Induced Cough Decreases Therapy Compliance  by Vegter, S. et al.
OBJECTIVES: To evaluate the level of compliance with antihypertensive medica-
tion among Greek hypertensive patients. Furthermore, to investigate the possible
association between non-compliance and patient profile as well as specific drug
categories. METHODS: A total of 2700 hypertensive patients participated and 2662
were analyzed in the study. The duration of the study was 9 months. Information
was collected on different antihypertensive drug categories along with epidemio-
logical data. Morisky scale was used in order to measure compliance. RESULTS: A
total of 57.5% of the responders were male (1530 patients) and 1130 were female.
Average age of responders was 63 years and average duration of hypertension was
8.6 years. 63.1% of the study population was found to be compliant with their
antihypertensive treatment (regardless of the type of antihypertensive treatment
the patient was receiving). From the Morisky scale, 36.2% of patients answered that
they sometimes forget to take their medication, 44.9% said that they were some-
times careless when it comes to taking their medicine, 26.9% that when they feel
better they forget to take their medicine and 18.4% of the study population an-
swered that when they feel worse, they relate this to their medication and discon-
tinue taking it. The factors found to influence compliance were the level of educa-
tion, the occupational status and the financial status of the patient as well as the
existence of conforming diseases such as duslipidemia and diabetes.
CONCLUSIONS: About four out of ten hypertensive patients fail to comply with
their prescribed treatment, increasing the possibility of poor control of their con-
dition. This may be an important obstacle in the assessment of the efficacy of any
pharmaceutical therapy and may influence the overall health levels of the patients,
since poorly controlled blood pressure may lead to the development of more seri-
ous conditions as Congestive Heart Failure and Coronary Heart Disease.
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OBJECTIVES:Antihypertensive agents have been shown to reduce the risk of major
cardiovascular events. However, there are no large effectiveness studies which
have assessed adherence to antihypertensive medications and major cardiovascu-
lar outcomes in high risk individuals who have recently suffered an ischemic
stroke. To evaluate the relationship between antihypertensive (AH) drug adher-
ence and cardiovascular (CV) outcomes among patients with a recent ischemic
stroke and to assess the validity of our approach. METHODS: A cohort of 14,227
patients with an ischemic stroke was assembled from individuals 65 years and
older who were treated with AH agents from 1999-2007 in the province of Quebec,
Canada. A nested case-control design was used to evaluate the occurrence of non-
fatal major CV outcomes, and mortality. Each case was matched to 15 controls by
age and cohort entry time. Medication possession ratio was used for AH agents
adherence level. Adjusted conditional logistic regression models were used to es-
timate the rate ratio of CV events. The validity of the approach was assessed by
evaluating the impact of adherence to CV protective and non-CV protective drugs.
RESULTS:Mean age was 75 years, 54% were male, 38% had coronary artery disease,
23% had diabetes, 47% dyslipidemia, and 14% atrial fibrillation or flutter. High
adherence to AH therapy decreased the risk of non-fatal vascular events compared
to lower level (Rate ratio: 0.77 (0.70-0.86). Male gender and CV disease were risk
factors for non-fatal vascular events. We observed a paradoxical relation between
adherence to several drugs and mortality risk. CONCLUSIONS: Adherence to AH
agents is associated with a risk reduction of non-fatal vascular events after a recent
ischemic stroke. Overestimation of an all-cause mortality reduction may be related
to frailty and comorbidity which may confound the apparent benefits of different
drugs.
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OBJECTIVES: A common adverse effect of angiotensin-converting enzyme inhibi-
tors (ACEi) is a persistent dry cough. Physicians and pharmacists who fail to recog-
nise dry cough to be ACEi related may prescribe cough suppressants (antitussives),
instead of recommended ACEi substitution. The aim of this study was to determine
the amount of antitussive treatment of ACEi-induced cough and the influence of
this on therapy compliance. METHODS: Prescription data from community phar-
macies between 2000 and 2012 were retrieved from the IADB.nl database in The
Netherlands. A prescription sequence symmetry analysis was used to determine
whether antitussive agents were prescribed more often following ACEi initiation
than the other way around. Therapy compliance was assessed using the proportion
of days covered (PDC) method; patients with a PDC 80% were considered
compliant. RESULTS: A total of 1898 starters of ACEi and antitussives within a
half-year time span were included. A significant excess of patients received anti-
tussives after ACEi initiation (1,269 versus 629), yielding a sequence ratio of 2.0 (CI:
1.8–2.2). The estimated proportion of patients with ACEi induced cough receiving
antitussives decreased over time: from 20.4% in 2000-2004 to 8.0% in 2008-2012.
Therapy compliance in patients receiving antitussives due to ACEi initiation was
52.4%, significantly lower than compliance in control patients, which was 75.2%
(P0.001). CONCLUSIONS: Many patients receive cough suppressants after ACEi
initiation. This suggests that ACEi induced cough is often either not recognized as
being ACEi related or is symptomatically treated. Such prescription behaviour is
ineffective and potentially harmful; it also decreases therapy compliance with ACE
inhibitors. The correct identification and management of this adverse drug effect is
an important aspect of pharmaceutical care.
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OBJECTIVES: To evaluate medication persistence in patients hypertensive chronic
who have different percentages of financial subsidy in a Program Benefit Manage-
ment (PBM). METHODS: We identified patients from 3 health care providers with
different percentages of subsidy to buy a medication using the same service in PBM
the first provider subsidizes 100%, the second subsidizes 90% (generic) and 70%
(brand) and third subsidizes 40%. We selected patients with age  40 years male
and female. The persistence analysis was made in the 12 months that followed
from the first acquisition within the using method MPR (Medication Possession
Ratio).The drugs was Antagonist of Angiotensin II Receptor (Losartan),Beta-Blocker
(Atenolol), Calcium Channel Blocker (amlodipine) and an inhibitor of angiotensin
converting enzyme (Enalapril). RESULTS: The persistence obtained with first pro-
vider (subsidizes 100%) Amlodipine n1266 and a persistence of 77.25%, n1016
Atenolol and a persistence of 44.39%, n680 and Enalapril a persistence of 90.00%
and Losartan n1157 and a persistence of 81.16% as an overall average of persis-
tence between the four drugs was 73.20%, the second provider (subsidizes 90% for
generic drugs and 70% for brand) obtained - Amlodipine n1948 and a persistence
of 78.49%, n2061 Atenolol and a persistence of 32.07%, n1265 Enalapril and
persistence 84.19% of Losartan and n2.166 and a persistence of 73.36% as an
overall average of persistence between four drugs 67.03% and the third provider
(subsidizes 40%), Amlodipine n1264 and a persistence of 9.34%, n1471 Atenolol
and a persistence of 9.11%, n941 Enalapril and a persistence of 36.88% and Losar-
tan n1917 and a persistence of 29.47% as a general average of persistence of the
four 21.20% drugs. CONCLUSIONS: The average persistence varies statistically sig-
nificantly with the percentage of subsidy the benefit influencing directly the per-
sistence of these populations, the greater the allowance / benefit was greater at the
rate of persistence between them.
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OBJECTIVES: To determine loss of health status, work productivity impairment,
and activity impairment associated with non-adherent cost-cutting in Russian hy-
pertension patients. METHODS: The study employed data from the 2011 Russia
National Health and Wellness Survey (NHWS; n10,039), a survey of demograph-
ics, health-related attitudes and behaviors, and health outcomes. Non-adherent
cost-cutting behaviors included taking less medication than prescribed, cutting
tablets in half, buying fewer tablets, not buying prescriptions recommended by the
physician, buying a less expensive alternative instead, or buying prescriptions less
often. Adherent behaviors included asking physician/ pharmacist for cheaper al-
ternatives, or using a discount card. Health status was assessed using the SF-12v2,
and work and activity impairment using the Work and Activity Impairment ques-
tionnaire (WPAI). Regression models quantified the burden associated with non-
adherent cost-cutting on health status and WPAI metrics, controlling for demo-
graphics, health history, insurance status, and comorbidities. RESULTS: Out of
1,712 diagnosed hypertension patients taking prescription medication for hyper-
tension, 37.5% reported using non-adherent cost-cutting behaviors, 28.2% reported
using adherent cost-cutting behaviors only, and 34.3% reported no cost-cutting
behaviors. After controlling for covariates, employed patients using non-adherent
strategies reported greater absenteeism (9.3% vs. 3.7%, p0.002), presenteeism
(29.2% vs. 21.8%, p0.001) and overall work productivity loss (33.8% vs. 24.3%,
p0.001) compared with employed patients who do not use those strategies.
Among all respondents, non-adherent cost-cutting was associated with lower ad-
justed health status (MCS: 42.0 vs. 44.4, p0.001, PCS: 40.3 vs. 41.3, p0.014) and
greater adjusted activity impairment (38.5% vs. 31.2%, p0.001). CONCLUSIONS:
Over a third of hypertension patients cut costs using strategies that interfere with
medication adherence. These patients suffer greater health-related impairments
in work and non-work activities and have lower health status. These patients
should be identified and guided to improve adherence to their prescription medi-
cations to facilitate better health outcomes.
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OBJECTIVES:Medication non-adherence and treatment satisfaction are significant
barriers to achieving treatment outcomes and associated with increased health
care costs among patients with hypertension. Using a novel patient registry, we
assessed factors associated with satisfaction and non-adherence to hypertension
medications.METHODS:We analyzed data from MediGuard.org, a free medication
monitoring service covering over 2.6 million members in the US, UK, France, Ger-
many, Spain, and Australia. As part of site operations, the service sends a quarterly
member survey to solicit feedback on their medications using the Treatment Sat-
isfaction Questionnaire for Medication (TSQM) and Medication Adherence Report
A377V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
